



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 021044-000600US

Assistant Commissioner for Patents
Washington, D.C. 20231

On

TOWNSEND and TOWNSEND and CREW LLP

By:

RECEIVED
SEP 17 2003
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

MASUDA *et al.*

Application No.: 09/998,667

Filed: December 3, 2001

For: TRAC1: MODULATORS OF
LYMPHOCYTE ACTIVATION

Examiner: Gibbs, Terra C.

Art Unit: 1653

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Examiner's Communication mailed February 26, 2003, Applicants submit herewith that the required paper copy and computer readable copy of the Sequence Listing submitted on April 18, 2002 fulfils all requirements under 37 C.F.R. §§ 1.821-1.825. Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

Amendments to the Specification begin on page 2 of this paper.

Remarks begin on page 3 of this paper.

Handwritten notes:
#11-01-
Seq.
Entered
in
part